...
首页> 外文期刊>Infection and immunity >Recombinant Mycobacterium bovis BCG Expressing the Sm14 Antigen of Schistosoma mansoni Protects Mice from Cercarial Challenge
【24h】

Recombinant Mycobacterium bovis BCG Expressing the Sm14 Antigen of Schistosoma mansoni Protects Mice from Cercarial Challenge

机译:表达曼氏血吸虫Sm14抗原的重组牛分枝杆菌卡介苗可保护小鼠免遭子弹头攻击

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The Sm14 antigen of Schistosoma mansoni was cloned and expressed in Mycobacterium bovis BCG as a fusion with the Mycobacterium fortuitum β-lactamase protein under the control of its promoter, pBlaF*; the protein was localized in the bacterial cell wall. The rBCG-Sm14 strain was shown to be relatively stable in cultured murine and bovine monocytes in terms of infectivity, bacterial persistence, and plasmid stability. The immunization of mice with rBCG-Sm14 showed no induction of anti-Sm14 antibodies; however, splenocytes of immunized mice released increased levels of gamma interferon upon stimulation with recombinant Sm14 (rSm14), indicating an induction of a Th1-predominant cellular response against Sm14. Mice immunized with one or two doses of rBCG-Sm14 and challenged with live S. mansoni cercaria showed a 48% reduction in worm burden, which was comparable to that obtained by immunization with three doses of rSm14 purified from Escherichia coli. The data presented here further enhance the status of Sm14 as a promising candidate antigen for the control of schistosomiasis and indicate that a one-dose regimen of rBCG-Sm14 could be considered a convenient means to overcome many of the practical problems associated with the successful implementation of a multiple-dose vaccine schedule in developing countries.
机译:克隆了曼氏血吸虫的Sm14抗原,并在牛分枝杆菌BCG中表达了它,该蛋白与分枝杆菌β-内酰胺酶蛋白融合,并在大肠杆菌的控制下表达。其启动子pBlaF *;该蛋白质位于细菌细胞壁中。就感染性,细菌持久性和质粒稳定性而言,rBCG-Sm14菌株在培养的鼠和牛单核细胞中显示相对稳定。用rBCG-Sm14免疫小鼠后,未诱导出抗Sm14抗体的诱导。但是,免疫小鼠的脾细胞在受到重组Sm14(rSm14)刺激后释放出增加水平的γ干扰素,这表明诱导了针对Sm14的Th1型主要细胞应答。用一剂或两剂rBCG-Sm14免疫的小鼠并用活的 S攻击。 mansoni 尾c的蠕虫负担降低了48%,这与三剂从大肠杆菌纯化的rSm14免疫接种所获得的蠕虫负担相当。此处提供的数据进一步增强了Sm14作为控制血吸虫病的有希望的候选抗原的地位,并表明一剂rBCG-Sm14方案可被认为是解决与成功实施相关的许多实际问题的便捷方法发展中国家的多剂量疫苗时间表。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号